Chengxiang Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chengxiang Guo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aijun Qiao
Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China
1 shared publication - Diru Yao
Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China
1 shared publication - Ebenezeri Erasto Ngowi
Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China
1 shared publication - Huan Tu
College of Computer and Electronic Information, Guangxi University, Nanning 530004, P. R. China
1 shared publication - Liangqing Hu
College of Computer and Electronic Information, Guangxi University, Nanning, China
1 shared publication - Longlong Wang
Department of Clinical Medicine of Integrated Traditional Chinese and Western Medicine, The Affiliated International Zhuang Medicine Hospital of Guangxi University of Chinese Medicine, Nanning 530200, China
1 shared publication
Latest Publications
- Open Access
Uncovering Potential Neutrophil-Related Biomarkers for Early AMI Diagnosis
Early diagnosis of AMI is crucial for improving patient outcomes, yet current clinical tools often lack the requisite sensitivity and specificity for reliable early detection. As neutrophils are the first innate immune responders mobilized following infarction, we employed an integrated multi-omics and machine learning approach to identify neutrophil-driven molecular signatures with diagnostic potential. By analyzing multiple peripheral blood transcriptomic datasets, we conducted differential expression and immune infiltration analyses, followed by machine learning-based feature selection to pinpoint key genes linked to neutrophil activity. Integration of these findings with single-cell transcriptomic data further clarified the neutrophil-specific expression patterns of candidate genes during AMI progression. Using a joint diagnostic model, we identified MCEMP1, NFE2, and AQP9 as the most informative predictors, with MCEMP1 emerging as the primary contributor. Experimental validation in a murine model of myocardial infarction (MI) confirmed rapid upregulation of MCEMP1 after injury, closely mirroring the kinetics of neutrophil infiltration. Collectively, these findings delineate a neutrophil-associated molecular profile of early AMI and highlight MCEMP1 as a promising noninvasive biomarker and a potential therapeutic target for modulating neutrophil-driven myocardial injury.
Open AccessUncovering Potential Neutrophil-Related Biomarkers for Early AMI Diagnosis
Early diagnosis of AMI is crucial for improving patient outcomes, yet current clinical tools often lack the requisite sensitivity and specificity for reliable early detection. As neutrophils are the first innate immune responders mobilized following infarction, we employed an integrated multi-omics and machine learning approach to identify neutrophil-driven molecular signatures with diagnostic potential. By analyzing multiple peripheral blood transcriptomic datasets, we conducted differential expression and immune infiltration analyses, followed by machine learning-based feature selection to pinpoint key genes linked to neutrophil activity. Integration of these findings with single-cell transcriptomic data further clarified the neutrophil-specific expression patterns of candidate genes during AMI progression. Using a joint diagnostic model, we identified MCEMP1, NFE2, and AQP9 as the most informative predictors, with MCEMP1 emerging as the primary contributor. Experimental validation in a murine model of myocardial infarction (MI) confirmed rapid upregulation of MCEMP1 after injury, closely mirroring the kinetics of neutrophil infiltration. Collectively, these findings delineate a neutrophil-associated molecular profile of early AMI and highlight MCEMP1 as a promising noninvasive biomarker and a potential therapeutic target for modulating neutrophil-driven myocardial injury.
- 5 July 2022
- Published by Springer Nature in Applied Intelligence
- Vol. 53 (5) , 1-25
Semisupervised anomaly detection of multivariate time series based on a variational autoencoder
- 5 July 2022
- Published by Springer Nature in Applied Intelligence
- Vol. 53 (5) , 1-25
Semisupervised anomaly detection of multivariate time series based on a variational autoencoder